AstraZeneca plc (LON:AZN) had its price target raised by HSBC Holdings plc from GBX 4,100 ($53.90) to GBX 4,150 ($54.56) in a research report report published on Monday, Marketbeat Ratings reports. The firm currently has a reduce rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on AZN. Liberum Capital restated a buy rating and set a GBX 5,500 ($72.31) target price on shares of AstraZeneca plc in a research report on Wednesday, June 14th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Thursday, June 15th. Jefferies Group LLC boosted their target price on AstraZeneca plc from GBX 5,000 ($65.74) to GBX 5,500 ($72.31) and gave the company a hold rating in a research report on Friday, June 16th. Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.94) target price on shares of AstraZeneca plc in a research report on Friday, June 16th. Finally, Credit Suisse Group restated a neutral rating and set a GBX 5,000 ($65.74) target price on shares of AstraZeneca plc in a research report on Monday, June 19th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of GBX 5,113.55 ($67.23).

Shares of AstraZeneca plc (LON:AZN) opened at 5154.00 on Monday. The stock’s market cap is GBX 65.25 billion. The firm has a 50-day moving average price of GBX 4,815.81 and a 200 day moving average price of GBX 4,905.16. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/12/astrazeneca-plc-azn-given-new-gbx-4150-price-target-at-hsbc-holdings-plc.html.

In other news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average price of GBX 4,370 ($57.45) per share, for a total transaction of £1,704.30 ($2,240.73).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.